49th Annual Meeting of the Infectious Diseases Society of America (IDSA) October 19, 2011

The 49th Annual Meeting of the Infectious Diseases Society of America will update infectious diseases clinicians and investigators with state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research and original reports of clinical, translational, and basic research. The event includes three and a half days of broad continuing education courses and comprehensive educational experiences in the major facets of infectious diseases: pathophysiology, diagnosis, treatment, and prevention. The meeting aims to bridge the widening gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research.

•Stan Block will present on the "Noninferior Immunologic Response of Quadrivalent, Live Attenuated Influenza Vaccine (Q/LAIV) Compared with Trivalent LAIV (T/LAIV) in Children."
•Kellie Ryan will present on the "Increased risk of RSV hospitalization among commercially-insured preterm infants non-compliant with palivizumab."
•Parthiv Mahadevia will present on the "Efficacy of palivizumab in reducing RSV hospitalization among high-risk 32-35 weeks gestational age infants."
•Roger Baxter will present on "A Post-licensure Evaluation of the Safety of Attenuated Influenza Vaccine in Children 2 to 4 Years of Age."
•Seth Toback will present on "A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine in Nonrecommended Children Younger Than 60 Months."
•Gabriel Escobar will present on the "Persistent Recurrent Wheezing in the Fifth Year of Life After Medically-Attended, Laboratory-Confirmed RSV Infection in Infancy."